Ezetimibe added to statin therapy after acute coronary syndromes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F15%3A00059607" target="_blank" >RIV/00023001:_____/15:00059607 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/15:N0000011
Result on the web
<a href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489" target="_blank" >http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1410489" target="_blank" >10.1056/NEJMoa1410489</a>
Alternative languages
Result language
angličtina
Original language name
Ezetimibe added to statin therapy after acute coronary syndromes
Original language description
BACKGROUND Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (}= 30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. CONCLUSIONS When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England journal of medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
372
Issue of the periodical within the volume
25
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
2387-2397
UT code for WoS article
000356354600005
EID of the result in the Scopus database
—